KBL Merger Corp. IV
Status: Deal Closed
U=S+W+R
W=S/2@11.5
R=S/10
| IPO Proceeds, $M | $115.00M |
|---|---|
| IPO Date | Jun 2, 2017 |
| CEO | Marlene Krauss, M.D. |
| Left Lead | Ladenburg Thalmann |
| IPO Cash in Trust | 101.4% |
| SPAC Tenor | 18+3+3+3+3+4+3+4 |
| IPO Sector |
Healthcare
Healthcare and related wellness |
| IPO Geography | Global |
| Target Company | 180 Life Sciences |
| Deal Announced | Jul 26, 2019 |
| Deal Size, $M | $242.90M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 26, 2020 |
| Amendment Vote | TBD |
| Closing Date | Nov 6, 2020 |
Formerly KBLM
ATNF
ATNFW
| Price | $2.31 $0.01 |
|---|---|
| Last closing price | $2.38 |
| H/L, today | $2.21 / $2.49 |
| H/L, 52-week | $0.36 / $11.14 |
| Volume, today | 64,108 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on KBL Merger Corp. IV:
- Structure and cap table
- 5 directors & officers
- 47 filings and events
- 5 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Marlene Krauss, M.D. | 71 | CEO & Director |
| Joseph A. Williamson | 63 | COO & Director |
| George Hornig | 62 | Chairman of the Board |
| Andrew Sherman | 47 | Director |
| Sherrill Neff | 64 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Ladenburg Thalmann | Joint BR | 4,700,000 | units |
| B. Riley FBR | Joint BR | 2,282,500 | |
| FBR Capital Markets | Joint BR | 2,282,500 | |
| Chardan | 435,000 | ||
| I-Bankers Securities | 300,000 | ||
| 10,000,000 | units | ||
| Up-Front UW fee | 2.50 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.